Gliflozins in Cardiovascular Disease: From Glycemic Control to CardiorenalMetabolic Protection

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular disease, heart failure, and type 2 diabetes mellitus. Intervention: SGLT-2 inhibitors (gliflozins: empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin) vs. Placebo. Primary outcome: Cardiovascular mortality, hospitalization for heart failure, and progression of renal disease.

doi:10.25258/ijddt.16.85s.136

October 6, 2026International Journal of Drug Delivery TechnologyOpen Access

Gliflozins in Cardiovascular Disease: From Glycemic Control to CardiorenalMetabolic Protection

View Full Paper

Ask AI

Bookmark

Share

Key result

SGLT-2 inhibitors reduce HbA1c by 0.5% to 1.1% and consistently lower heart failure hospitalizations, cardiovascular mortality, and renal disease progression across diabetes and heart failure populations.

Why the study?

This review summarizes findings on the cardiovascular benefits, molecular mechanisms of action, safety profiles, and emerging applications of SGLT-2 inhibitors in managing cardiovascular diseases.

Do SGLT-2 inhibitors reduce cardiovascular mortality, hospitalizations for heart failure, and progression of renal disease in patients with cardiovascular disease, heart failure, and type 2 diabetes mellitus?

Key Points

To review the cardiovascular benefits, underlying molecular mechanisms, safety profiles, and emerging applications of SGLT-2 inhibitors beyond glycemic control.
Narrative review summarizing findings from large-scale randomized controlled trials, meta-analyses, and molecular studies evaluating SGLT-2 inhibitors in cardiovascular and renal disease.
Assessed trials evaluating canagliflozin (CANVAS Program), dapagliflozin (DECLARE-TIMI 58, DAPA-HF), ertugliflozin (VERTIS-CV), and dual SGLT1/SGLT2 inhibitor sotagliflozin (SCORED, SOLOIST-WHF).
Evidence across trials demonstrates consistent reductions in hospitalizations for heart failure, cardiovascular mortality, and progression of chronic renal disease in patients with type 2 diabetes and heart failure.
Dapagliflozin reduced worsening heart failure or cardiovascular death in patients with reduced ejection fraction including those without diabetes, while sotagliflozin reduced composite cardiovascular events in trials such as SCORED and SOLOIST-WHF.
Cardioprotective effects involve modulation of myocardial metabolism, inflammation, and fibrosis, alongside recognized safety considerations such as an increased risk of lower-limb amputation identified in the CANVAS Program.

Structured PICO

Do SGLT-2 inhibitors reduce cardiovascular mortality, hospitalizations for heart failure, and progression of renal disease in patients with cardiovascular disease, heart failure, and type 2 diabetes mellitus?

P

Population

Patients with cardiovascular disease, heart failure, chronic kidney disease, and/or type 2 diabetes mellitus treated with SGLT-2 inhibitors across major cardiovascular outcome trials.

I

Intervention

Sodium-dependent glucose cotransporter-2 (SGLT-2) inhibitors (gliflozins) as a class, including oral agents canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and the dual SGLT2/SGLT1 inhibitor sotagliflozin.

C

Comparator

Placebo (in most major cardiovascular outcome trials discussed).

O

Outcome

Cardiovascular mortality, hospitalizations for heart failure, and progression of renal disease.hard clinical

Limitations

Most major cardiovascular outcome trials were placebo-controlled rather than direct head-to-head comparisons between active SGLT-2 inhibitors.
Apparent differences in efficacy among individual agents rely on indirect comparisons or network meta-analyses across trials with varying baseline risk profiles, follow-up periods, and endpoint definitions.
The precise molecular mechanisms by which SGLT-2 inhibitors confer cardiovascular protection remain incompletely understood.
Most major cardiovascular outcome trials were placebo-controlled rather than head-to-head comparisons between active SGLT2 inhibitors.
Network meta-analyses compare treatments across trial populations with varying baseline cardiovascular risk profiles, follow-up periods, endpoint definitions, and background therapies, preventing definitive evidence of clinical superiority of one agent over another.

Implication

This review summarizes the class-wide and agent-specific cardiorenal-metabolic benefits of SGLT-2 inhibitors in reducing heart failure hospitalizations, cardiovascular mortality, and kidney disease progression independently of glycemic control.

Abstract

Sodium-dependent glucose cotransporter-2 (SGLT-2) inhibitors, commonly known as gliflozins, have become crucial in managing cardiovascular diseases (CVDs), particularly in individuals with heart failure and type 2 diabetes mellitus (T2DM).This review summarizes findings from various scientific studies on the cardiovascular benefits, mechanisms of action, safety profiles, and emerging applications of SGLT-2 inhibitors.Evidence from large-scale randomized controlled trials and meta-analyses highlights their effectiveness in reducing cardiovascular mortality, hospitalizations for heart failure, and progression of renal disease.Additionally, the review examines the molecular mechanisms at play, such as modulation of myocardial metabolism, inflammation, and fibrosis, which contribute to the therapeutic effects of SGLT-2 inhibitors in managing broader cardiovascular risks.This includes potential applications in non-diabetic populations and in combination therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2026 study conducted a review in Cardiovascular disease, heart failure, and type 2 diabetes mellitus. SGLT-2 inhibitors (gliflozins: empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin) vs. Placebo was evaluated on Cardiovascular mortality, hospitalization for heart failure, and progression of renal disease. SGLT-2 inhibitors reduce HbA1c by 0.5% to 1.1% and consistently lower heart failure hospitalizations, cardiovascular mortality, and renal disease progression across diabetes and heart failure populations.

synapsesocial.com/papers/6ae28e38cbadf70daf6c40bd https://doi.org/10.25258/ijddt.16.85s.136

View Full Paper

Ask AI

Bookmark

Share

Gliflozins in Cardiovascular Disease: From Glycemic Control to CardiorenalMetabolic Protection

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Gliflozins in Cardiovascular Disease: From Glycemic Control to CardiorenalMetabolic Protection

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading